2025
ANIFROLUMAB EFFECTS ON RESPONSE TO INFLUENZA VACCINE IN SLE
Arriens C, Askanase A, Machua W, Koumpouras F, Smith K, Guthridge J, James J, Merrill J. ANIFROLUMAB EFFECTS ON RESPONSE TO INFLUENZA VACCINE IN SLE. The Journal Of Rheumatology 2025, 52: 231-232. DOI: 10.3899/jrheum.2025-0390.pv244.Peer-Reviewed Original ResearchGeometric mean titersResponse to influenza vaccinationStandard-of-care treatmentSLEDAI Flare IndexInfluenza vaccineAdverse eventsVaccine responseSLE patientsHemagglutination inhibitionEnzyme-linked immunosorbent assayWeek 8Anifrolumab groupControl groupContext of influenza vaccinesModerate to severe SLESeasonal influenza virus vaccinesBaseline to week 8Interferon SignalingAnti-influenza IgGInfluenza virus vaccineGeometric mean foldDiscontinuation of treatmentHemagglutinin inhibition assayAdult SLE patientsHerpes zoster reactivation
2020
The kinetics of humoral response and its relationship with the disease severity in COVID-19
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Communications Biology 2020, 3: 780. PMID: 33311543, PMCID: PMC7733479, DOI: 10.1038/s42003-020-01526-8.Peer-Reviewed Original ResearchConceptsHumoral responseDisease severityReceptor-binding domainAntibody titersSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Titers of NAbsGeometric mean titersCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019Disease courseMean titersCoronavirus 2Antibody responseIgG antibodiesRisk factorsIg levelsImmunoglobulin ADisease 2019Severe casesModerate infections
2018
2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
Anderson E, Lopman B, Yi J, Yildirim I, Creech C, El-Khorazaty J, Shane A, Edwards K. 2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination. Open Forum Infectious Diseases 2018, 5: s675-s676. PMCID: PMC6255677, DOI: 10.1093/ofid/ofy210.1933.Peer-Reviewed Original ResearchGeometric mean titersAntibiotic exposureLogistic regression modelsRV vaccinesMultivariable logistic regression modelConcomitant antibiotic useRV immunizationLast doseVaccine doseVaccine groupImmunized childrenPrimary outcomeRotavirus immunizationAntibiotic administrationMean titersRegression modelsVaccine dosesSerological responseTreatment allocationAntibiotic useInclusion criteriaVaccine studiesImmune responseTreatment groupsSeroresponses
2015
Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso
Tall H, Yaro S, Kpoda H, Ouangraoua S, Trotter C, Lafourcade B, Findlow H, Bai X, Martin C, Nwakamma I, Ouedraogo J, Gessner B, Borrow R, Mueller J. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso. Clinical Infectious Diseases 2015, 61: s540-s546. PMID: 26553686, PMCID: PMC4639492, DOI: 10.1093/cid/civ519.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsAntibodies, BacterialBlood Bactericidal ActivityBurkina FasoChildChild, PreschoolComplement System ProteinsFemaleHumansImmunoglobulin GInfantMaleMass VaccinationMeningitis, MeningococcalMeningococcal VaccinesNeisseria meningitidis, Serogroup ARabbitsSeroepidemiologic StudiesYoung AdultConceptsAntibody titersSerum bactericidal antibody titersVaccine-eligible age groupsBactericidal antibody titersGeometric mean titersAfrican meningitis beltPopulation-level immunitySpecific antibody titersMass immunization campaignOptimal vaccination strategyImmunoglobulin G concentrationLong-term controlPsA-TTMean titersVaccine coverageProtective antibodiesMeningitis beltBlood drawVaccination strategiesImmunization campaignRabbit complementGroup AHigh seroprevalenceStandardized interviewAge groups
2012
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Kabwende A, Adegnika A, Mordmüller B, Issifou S, Kremsner P, Sacarlal J, Aide P, Lanaspa M, Aponte J, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali A, Mtoro A, Hamad A, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kaboré B, Sombié O, Guiguemdé R, Ouédraogo J, Hamel M, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson K, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods J, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante K, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng H, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou W, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal Of Medicine 2012, 367: 2284-2295. PMID: 23136909, PMCID: PMC10915853, DOI: 10.1056/nejmoa1208394.Peer-Reviewed Original ResearchConceptsPhase 3 trialVaccine efficacySevere malariaWeeks of ageProtocol populationTreat populationClinical malariaCandidate malaria vaccine RTSOngoing phase 3 trialsAnti-circumsporozoite antibodiesMalaria vaccine RTSCoprimary end pointsSerious adverse eventsGeometric mean titersMonths of ageComparator vaccineAdverse eventsFirst doseFirst vaccinationMalaria episodesThird doseMean titersCox regressionMalaria vaccineAfrican infantsTrack B Clinical Science
Kyrychenko T, Dubynska G, Koval T, Kaidashev I, Korshenko V, Rono K, Kibuuka H, Maganga L, Kosgei J, Sekiziyivu A, Sanga E, Ngetich E, Valenzuela A, Michael N, Robb M, Markowitz M, Evering T, Figueroa A, Rodriguez K, La Mar M, Garmon D, Sahi V, Mohri H, Asher A, Santos G, Dokubo E, Martin J, Deeks S, Tobler L, Busch M, Hunt P, Page K, Weber R, Smith C, Group D, Mannheimer S, Wang L, Tieu H, del Rio C, Buchbinder S, Wilton L, Glick S, Cummings V, Mayer K, Hutchinson A, Sansom S, Farnham P, Davis R, Dzoro S, Moyo S, Gaseitsiwe S, Musonda R, Novitsky V, Essex M, Ouma K, Basavaraju S, Okonji J, Williamson J, Mills L, Zeh C, Vallabhaneni S, Chandy S, Heylen E, Ekstrand M, Manasa J, McGrath N, Lessells R, Skingsley A, Newell M, de Oliveira T, Rawizza H, Chaplin B, Meloni S, Okonkwo P, Kanki P, Team T, Gale H, Gitterman S, Gordin F, Benator D, Kan V, Meya D, Rajasingham R, Rolfes M, Birkenkamp K, Boulware D, Bulterys P, Le T, Quang V, Nelson K, Lloyd‐Smith J, Luetkemeyer A, Rosenkranz S, Lu D, Lizak P, Ive P, Swindells S, Benson C, Grinsztejn B, Sanne I, Havlir D, Aweeka F, A5221 A, Sterling T, Benson C, Shang N, Miro J, Grinsztejn B, Chaisson R, Lucchetti A, Sanchez J, Scott N, Villarino E, Group T, McIlleron H, Martinson N, Denti P, Mashabela F, Hunt J, Shembe S, Hull J, Haas D, Msandiwa R, Cohn S, Chaisson R, Dooley K, Team T, Everitt D, Winter H, Egizi E, Everitt D, Murray S, Diacon A, Dawson R, Hutchings J, Van Niekerk C, Egizi E, Becker P, Hafkin J, Modongo C, Newcomb C, Lowenthal E, MacGregor R, Steenhoff A, Friedman H, Bisson G, Fitzgerald D, Jansen P, Chipungu C, Dindi V, Fielder J, Pfaff C, Bygrave H, Simons S, Munyaradzi D, Nyagadza B, Metcalf C, Ncube K, Van Den Broucke S, Mupfumi L, Mason P, Zinyowera S, Mutetwa R, Wallis R, Diacon A, Dawson R, Venter A, Friedrich S, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Kadyszewski E, Brust J, Shah N, van der Merwe T, Bamber S, Mngadi A, Ning Y, Heo M, Moll A, Loveday M, Lalloo U, Friedland G, Gandhi N, Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, Spiegelman D, Mugusi F, Mehta S, Fawzi W, Re V, Tate J, Kallan M, Lim J, Goetz M, Klein M, Rimland D, Rodriguez‐Barradas M, Butt A, Gibert C, Brown S, Kostman J, Strom B, Reddy R, Justice A, Localio R, Amorosa V, Umbleja T, Johnson V, Kang M, Luetkemeyer A, Bardin M, Haas D, Chung R, Yesmin S, Coughlin K, Martinez A, Adams M, Alston‐Smith B, Tebas P, Peters M, Kahn J, Xu J, Kapogiannis B, Rudy B, Liu N, Gonin R, Wilson C, Worrell C, Squires K, Kojic E, Cespedes M, Umbleja T, Kang M, Aberg J, Allen R, Grinsztein B, Firnhaber C, Webster‐Cyriaque J, Palefsky J, Godfrey C, Saah A, Cu‐Uvin S, Rangaka M, Boulle A, Wilkinson R, van Cutsem G, Goemaere E, Goliath R, Titus R, Mathee S, Maartens G, Shet A, Holla S, Raman V, Dinakar C, Ashok M, Dufouil C, Richert L, Bruyand M, Amieva H, Dauchy F, Dartigues J, Neau D, Dabis F, Morlat P, Bonnet F, Chene G, Group A, Nigo M, Walker A, Lucido D, Shah A, Skliut M, Mildvan D, Sahasrabuddhe V, Castle P, Follansbee S, Borgonovo S, LaMere B, Tokugawa D, Darragh T, Boyle S, Sadorra M, Tang S, Wentzensen N, Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri S, Craig C, Vourvahis M, Heera J, Valdez H, Brown T, Rinehart A, Portsmouth S, Gallant J, Koenig E, Andrade‐Villanueva J, Chetchotisakd P, Dejesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Ramanathan S, Szwarcberg J, Rhee M, Cheng A, Palella F, Tebas P, Gazzard B, Ruane P, Shamblaw D, Flamm J, Fisher M, van Lunzen J, Ebrahimi R, White K, Guyer B, Graham H, Fralich T, Elion R, Molina J, Arribas‐Lopez J, Cooper D, Maggiolo F, Wilkins E, Conway B, Liu Y, Zhong L, Margot N, Szwarcberg J, Rhee M, Cheng A, Raffi F, Rachlis A, Stellbrink H, Hardy W, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Almond S, Margolis D, Min S, Team T, Karasi J, Musonera F, Iranyumviye K, Servais J, Devaux C, Binagwaho A, Arendt V, Shafer R, Zolopa A, Schmit J, Rimsky L, Van Eygen V, Vingerhoets J, Thys K, Aerssens J, Stevens M, Picchio G, van Zyl G, Claassen M, Engelbrecht S, de Oliveira T, Preiser W, Wood N, Travers S, Shafer R, Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun‐Vézinet F, Mentré F, Descamps D, Yeni P, Grinsztejn B, De Castro N, Arnold V, Veloso V, Morgado M, Pilotto J, Brites C, Madruga J, Barcellos N, Santos B, Vorsatz C, Grondin C, Santini‐Oliveira M, Patey O, Delaugerre C, Chêne G, Molina J, group A, Venuto C, Mollan K, Ma Q, Daar E, Sax P, Fischl M, Collier A, Smith K, Lu D, Tierney C, Morse G, Team A, Haas D, Acosta E, Vardhanabhuti S, Ribaudo H, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan E, Hitti J, McMahon D, Group F, Gandhi M, Greenblatt R, Bacchetti P, Jin C, Cohen M, Dehovitz J, Anastos K, Gange S, Liu C, Hanson S, Aouizerat B, Study W, Gervasoni C, Baldelli S, Cerea M, Meraviglia P, Landonio S, Simioni M, Gazzaniga A, Galli M, Rizzardini G, Clementi E, Cattaneo D, Grinsztejn B, Hosseinipour M, Swindells S, Ribaudo H, Eron J, Chen Y, Wang L, Ou S, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim J, Kumwenda J, Pilotto J, Godbole S, Chariyalertsak S, Santos B, Mayer K, Eshleman S, Piwowar‐Manning E, Cottle L, Makhema J, Mills L, Panchia R, Sanne I, Elharrar V, Havlir D, Cohen M, Team F, Kanki P, Chang C, Meloni S, Rawizza H, Jolayemi T, Banigbe‐Aluko B, Okonkwo P, team H, Rewari B, Shaukat M, Kabra S, Srikantiah P, Lundgren J, Europe C, Colombero C, Rocco C, Mecikovsky D, Bologna R, Aulicino P, Sen L, Mangano A, Nielsen‐Saines K, Mirochnick M, Kumwenda N, Joao E, Kreitchmann R, Pinto J, Santos B, Parsons T, Richardson P, Taha T, Mofenson L, Sato P, Kearney B, Fowler M, Hazra R, Viani R, Acosta E, Zheng N, Alvero C, O'Gara E, Petzold E, Heckman B, Steimers D, Song I, Piscitelli S, Wiznia A, Team P, Cotton M, Cassim H, Pavía‐Ruz N, Ross L, Ford S, Givens N, Cheng K, Sievers J, Tudor‐Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, Kakuda T, Nijs S, Tambuyzer L, Tomaka F, Nachman S, Acosta E, Zheng N, Teppler H, Homony B, Xu X, Alvero C, Handelsman E, Worrell C, Graham B, Toye M, Petzold E, Wiznia A, Group A, Miruka A, Achieng R, Aoko A, Tarus J, Sigei C, Yegon P, Maswai J, Sawe F, Shaffer D, Crawford K, Kanjanavanit S, Puthanakit T, Kosalaraksa P, Hansudewechakul R, Ngampiyaskul C, Pinyakorn S, Luesomboon W, Vonthanak S, Ananworanich J, Ruxrungtham K, group P, Miller T, Wang J, Jacobson D, Takemoto J, Sharma T, Geffner M, Libutti D, Siminski S, Dooley L, Somarriba G, Graham P, Gerschenson M, van Ramshorst M, Struthers H, McIntyre J, Peters R, Himes S, Scheidweiler K, Tassiopoulos K, Kacanek D, Hazra R, Rich K, Huestis M, Study F, O'Brien M, Nardi M, Montenont E, Valdes V, Hu L, Merolla M, Gettenberg G, Aberg J, Bhardwaj N, Berger J, Kelesidis T, Kendall M, Yang O, Currier J, McComsey G, Kitch D, Sax P, Tierney C, Jahed N, Melbourne K, Ha B, Brown T, Bloom A, Fedarko N, Daar E, A5224s A, Schouten J, Wit F, Stolte I, van der Valk M, Geerlings S, de Wolf F, Prins M, Reiss P, Sax P, Sypek A, Morris B, Losina E, Paltiel A, Seage G, Walensky R, Weinstein M, Eron J, Freedberg K. Track B Clinical Science. Journal Of The International AIDS Society 2012, 15: 18439-01. PMCID: PMC3499900, DOI: 10.7448/ias.15.5.18439.Peer-Reviewed Original ResearchSecond-line antiretroviral therapyFirst-line antiretroviral therapyPlasma HIV-1 RNANNRTI resistance-associated mutationsHIV-1-infected adultsIsoniazid preventive therapyRitonavir-boosted protease inhibitorAcute HIV infectionCardiovascular risk factorsCD4 cell countCombination antiretroviral therapyHIV-1-infected patientsSerious adverse eventsATV/rCells/mm3Genotypic resistance testingGeometric mean titersLow-level viremiaTDF/FTCCommon adverse eventsCAP/CTMBody mass indexHIV-1 RNAAZT/3TC/nevirapineAZT/3TC/NVP
2003
Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors
Hudnall SD, Chen T, Rady P, Tyring S, Allison P. Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion 2003, 43: 85-90. PMID: 12519435, DOI: 10.1046/j.1537-2995.2003.00272.x.Peer-Reviewed Original ResearchConceptsHHV-8 seroprevalenceBlood donorsDonor bloodPrimary effusion B-cell lymphomaABO blood group BHigh HHV-8 seroprevalenceHuman herpesvirus 8 seroprevalenceLatent HHV-8 antigensHealthy adult blood donorsBlood donor unitsBuffy coat DNAHHV-8 antigensHHV-8 ORF26HHV-8 viremiaSensitive indirect immunofluorescenceGeometric mean titersAdult blood donorsHHV-8 antibodiesHHV-8 DNABlood-borne virusesHuman herpesvirus 8B-cell lymphomaBlood group BDonor blood samplesHuman tumor virusAn open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine
Schoen RT, Deshefy-Longhi T, Van-Hoecke C, Buscarino C, Fikrig E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clinical Therapeutics 2003, 25: 210-224. PMID: 12637121, DOI: 10.1016/s0149-2918(03)90027-0.Peer-Reviewed Original ResearchConceptsLyme disease vaccineFirst booster doseSecond booster doseBooster doseAdverse eventsBooster dosesPrimary seriesMonth 24Disease vaccineClinical trialsEfficacy trialsImmune responseIncidence of AEsPattern of AEsLyme diseaseMost adverse eventsGeometric mean titersTotal IgG antibodiesProportion of subjectsPositive test resultsSeroprotective levelsBooster vaccinationMonth 36Third vaccinationDiary cards
2001
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: A Prospective Study
Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ. Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: A Prospective Study. JAMA 2001, 286: 3083-3088. PMID: 11754673, DOI: 10.1001/jama.286.24.3083.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusViral capsid antigenCases of MSGeometric mean titersHealth Study IIMultiple sclerosisSerum antibody titersRelative riskAntibody titersDisease onsetEBNA-2Health StudyRole of EBVNurses' Health Study IIEBV viral capsid antigenEpstein-Barr virus antibodiesEtiology of MSOccurrence of MSHealthy age-matched controlsNurses' Health StudyCorresponding relative risksCase-control studyAge-matched controlsCMV antigensEBV antibodies
1998
Serologic and Molecular Evidence of Human Herpesvirus 8 Activation in Renal Transplant Recipients
Hudnall S, Rady P, Tyring S, Fish J. Serologic and Molecular Evidence of Human Herpesvirus 8 Activation in Renal Transplant Recipients. The Journal Of Infectious Diseases 1998, 178: 1791-1794. PMID: 9815236, DOI: 10.1086/314482.Peer-Reviewed Original ResearchConceptsRenal transplant patientsGeometric mean titersHealthy adultsTransplant patientsPolymerase chain reactionRenal transplant populationRenal transplant recipientsHIV-positive adultsHuman immunodeficiency virusViral DNATransplant recipientsTransplant groupTransplant populationMean titersImmunodeficiency virusImmunocompromised populationsSerum antibodiesKaposi's sarcomaPositive adultsSerologic resultsIndirect immunofluorescenceWhole bloodChain reactionAdultsPatients
1990
Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly?
Cartter M, Renzullo P, Helgerson S, Martin S, Jekel J. Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly? Infection Control And Hospital Epidemiology 1990, 11: 473-8. PMID: 2230050, DOI: 10.1086/646214.Peer-Reviewed Original ResearchConceptsNursing homesUnvaccinated residentsClinical illnessVaccine effectivenessThird outbreakInfluenza outbreaksInfluenza vaccination ratesInfluenza vaccine effectivenessGeometric mean titersHemagglutination inhibition antibodiesVaccinated residentsConnecticut nursing homesInfluenza seasonInfluenza vaccineMean titersVaccination ratesHI antibodyInfluenza ARelative riskHI titersRetrospective investigationIllnessTitersAntibodiesOutbreak
1987
EPIZOOTIOLOGY OF HANTAVIRUS INFECTIONS IN BALTIMORE: ISOLATION OF A VIRUS FROM NORWAY RATS, AND CHARACTERISTICS OF INFECTED RAT POPULATIONS
CHILDS J, KORCH G, GLASS G, LEDUC J, SHAH K. EPIZOOTIOLOGY OF HANTAVIRUS INFECTIONS IN BALTIMORE: ISOLATION OF A VIRUS FROM NORWAY RATS, AND CHARACTERISTICS OF INFECTED RAT POPULATIONS. American Journal Of Epidemiology 1987, 126: 55-68. PMID: 3109236, DOI: 10.1093/oxfordjournals.aje.a114662.Peer-Reviewed Original ResearchConceptsHantavirus infectionGeometric mean titersPrevalence of antibodiesAntibody prevalence ratesAntibody reactivity patternsMonoclonal antibody reactivity patternsAge-related mechanismsMean titersSerologic testsHigh prevalenceInfected ratsPrevalence ratesPresence of ratsRatsInfectionEnzootic natureUrban ratsSix-year periodHuman exposureRat massVirusPrevalenceAntibodiesHantavirusesUnited States
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply